Literature DB >> 12831873

Chronic intermittent nicotine administration attenuates traumatic brain injury-induced cognitive dysfunction.

S L Verbois1, D M Hopkins, S W Scheff, J R Pauly.   

Abstract

Traumatic brain injury (TBI) initiates immediate and secondary neuropathological cascades that can result in persistent neurological dysfunction. Previous studies from our laboratory have shown that experimental rat brain injury causes a rapid and persistent decrease in CNS alpha7* nicotinic cholinergic receptor (nAChr) expression. The purpose of this study was to investigate whether intermittent nicotine injections could improve cognitive performance in the Morris water maze (MWM) following experimental brain injury. Adult male rats were anesthetized and subjected to a 1.5 mm controlled cortical impact (CCI) injury of the somatosensory cortex. Animals received twice daily i.p. nicotine injections for 11 days prior to CCI, 11 days following CCI or during both pre- and post-surgical intervals. MWM training was initiated 12 days post-injury. In the training phase of cognitive testing, twice-daily nicotine treatment following injury attenuated trauma-induced deficits in the distance traveled to reach the escape platform. This group of animals also had improvements in several measures of the probe test, including time spent, distance traveled and total entries into the target quadrant. TBI caused significant deficits in alpha7* nAChr expression in several regions of the hippocampus and cerebral cortex, which were largely unaffected by intermittent nicotine treatment. However, nicotine treatment up-regulated [(3)H]-epibatidine binding to non-alpha7* nAChrs, attenuating TBI-induced deficits in receptor expression in several brain regions evaluated. These results suggest that nicotine is efficacious at attenuating CCI-induced cognitive deficits in a manner independent of changes in alpha7* nAChr expression, perhaps via up-regulation of non-alpha7* nAChrs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12831873     DOI: 10.1016/s0306-4522(03)00206-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  17 in total

1.  Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspirone.

Authors:  Adam S Olsen; Christopher N Sozda; Jeffrey P Cheng; Ann N Hoffman; Anthony E Kline
Journal:  J Neurotrauma       Date:  2012-04-23       Impact factor: 5.269

Review 2.  Alterations in Cholinergic Pathways and Therapeutic Strategies Targeting Cholinergic System after Traumatic Brain Injury.

Authors:  Samuel S Shin; C Edward Dixon
Journal:  J Neurotrauma       Date:  2015-06-29       Impact factor: 5.269

3.  High therapeutic potential of positive allosteric modulation of α7 nAChRs in a rat model of traumatic brain injury: proof-of-concept.

Authors:  Joshua W Gatson; James W Simpkins; Victor V Uteshev
Journal:  Brain Res Bull       Date:  2015-01-31       Impact factor: 4.077

Review 4.  Biologic and plastic effects of experimental traumatic brain injury treatment paradigms and their relevance to clinical rehabilitation.

Authors:  Alexandra N Garcia; Mansi A Shah; C Edward Dixon; Amy K Wagner; Anthony E Kline
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

Review 5.  Natural Compounds as a Therapeutic Intervention following Traumatic Brain Injury: The Role of Phytochemicals.

Authors:  Stephen W Scheff; Mubeen A Ansari
Journal:  J Neurotrauma       Date:  2016-12-21       Impact factor: 5.269

Review 6.  Does traumatic brain injury increase risk for substance abuse?

Authors:  James M Bjork; Steven J Grant
Journal:  J Neurotrauma       Date:  2009-07       Impact factor: 5.269

7.  Validation of a 2-day water maze protocol in mice.

Authors:  Maria Gulinello; Michael Gertner; Guadalupe Mendoza; Brian P Schoenfeld; Salvatore Oddo; Frank LaFerla; Catherine H Choi; Sean M J McBride; Donald S Faber
Journal:  Behav Brain Res       Date:  2008-09-11       Impact factor: 3.332

8.  Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.

Authors:  Anthony E Kline; Rose L McAloon; Kate A Henderson; Utsav K Bansal; Bhaskar M Ganti; Rashid H Ahmed; Robert B Gibbs; Christopher N Sozda
Journal:  J Neurotrauma       Date:  2010-10-28       Impact factor: 5.269

Review 9.  The therapeutic promise of positive allosteric modulation of nicotinic receptors.

Authors:  Victor V Uteshev
Journal:  Eur J Pharmacol       Date:  2014-02-12       Impact factor: 4.432

10.  Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease.

Authors:  Hanjun Guan; Yinxing Liu; Abigail Daily; Sara Police; Myung-Hee Kim; Salvatore Oddo; Frank M LaFerla; James R Pauly; M Paul Murphy; Louis B Hersh
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.